Live Analyst Rating Changes 1656 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Matt Phipps
WB
Matt Phipps
William Blair
Wall Street Analyst
★☆☆☆☆
#2458
on 13Foresight · ranked by our own returns
36%
Success Rate
-4.0%
Average Return
17 of 47 calls profitable · -132.1% vs benchmark
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 36% of Matt Phipps's ratings turned a profit when each position was held for 1 year — averaging -4.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

187 Buy 62 Hold 0 Sell
Matt's Stock Coverage 38 ratings · 2026-06-22
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
INCY
Incyte
 Jun 15, 2026 HOLD Buy
+1.5% avg upside
47 analysts
 — -2.9%
CNTX
Context Therapeutics
 Jun 15, 2026 BUY Strong Buy
+873.3% avg upside
12 analysts
 — ·
GMAB
Genmab
 Jun 15, 2026 BUY Strong Buy
+38.3% avg upside
26 analysts
 — ·
CLYM
Climb Bio
 Jun 11, 2026 BUY Strong Buy
+57.9% avg upside
18 analysts
 — ·
EVMN
Evommune, Inc.
 Jun 10, 2026 BUY Strong Buy
+134.5% avg upside
12 analysts
 — -2.1%
CGEM
Cullinan Management
 Jun 08, 2026 BUY Strong Buy
+125.7% avg upside
15 analysts
 — +8.7%
AUTL
Autolus Therapeutics
 Jun 02, 2026 BUY Strong Buy
+605.8% avg upside
16 analysts
 — -16.6%
JBIO
Jade Biosciences
 Jun 01, 2026 BUY Strong Buy
+232.9% avg upside
16 analysts
 — -9.5%
JSPR
Jasper Therapeutics
 Jun 01, 2026 HOLD Strong Buy
+6361.2% avg upside
17 analysts
 — -11.8%
UPB
Upstream Bio, Inc.
 May 19, 2026 BUY Strong Buy
+514.9% avg upside
9 analysts
 — -19.7%
INSM
Insmed
 May 18, 2026 BUY Strong Buy
+82.2% avg upside
36 analysts
 — -8.1%
KROS
Keros Therapeutics
 May 14, 2026 HOLD Strong Buy
+139.0% avg upside
21 analysts
 — -4.5%
TENX
Tenax Therapeutics
 May 12, 2026 BUY Strong Buy
+213.9% avg upside
8 analysts
 — +1.6%
JANX
Janux Therapeutics Inc
 May 08, 2026 BUY Strong Buy
+217.2% avg upside
21 analysts
$14.00
1.54% Downside
 -0.2%
IMA
ImageneBio
 May 08, 2026 BUY Strong Buy
+179.7% avg upside
12 analysts
 — +7.4%
ARGX
Argenx Se
 May 07, 2026 BUY Strong Buy
-15.8% avg upside
46 analysts
 — +12.1%
NAMS
NewAmsterdam Pharma Company
 May 07, 2026 BUY Strong Buy
+56.4% avg upside
18 analysts
 — -14.4%
XNCR
Xencor
 May 06, 2026 BUY Strong Buy
+160.0% avg upside
27 analysts
$13.00
2.84% Upside
 -13.4%
CMPX
Compass Therapeutics
 May 05, 2026 BUY Strong Buy
+373.3% avg upside
19 analysts
 — +3.6%
AMGN
Amgen
 May 01, 2026 BUY Buy
-11.6% avg upside
57 analysts
 — +3.1%
BMY
Bristol-Myers Squibb
 Apr 30, 2026 HOLD Buy
+9.2% avg upside
42 analysts
 — -10.9%
ABBV
AbbVie
 Apr 29, 2026 BUY Buy
+2.3% avg upside
43 analysts
$203.00
6.33% Downside
 +11.1%
AXSM
Axsome Therapeutics
 Jan 03, 2026 BUY Strong Buy
-10.5% avg upside
28 analysts
 — +46.9%
IONS
Ionis Pharmaceuticals
 Oct 11, 2025 BUY Strong Buy
+13.3% avg upside
43 analysts
$116.76
57.58% Upside
 +3.8%
DNTH
Dianthus Therapeutics
 Sep 13, 2025 BUY Strong Buy
+8.8% avg upside
29 analysts
 — +122.7%
INKT
MiNK Therapeutics
 Aug 29, 2025 HOLD Strong Buy
+81.2% avg upside
6 analysts
 — -20.7%
AGEN
Agenus
 Aug 29, 2025 HOLD Strong Buy
+164.7% avg upside
17 analysts
 — -14.3%
VRTX
Vertex Pharmaceuticals
 Jun 28, 2025 BUY Strong Buy
-2.6% avg upside
61 analysts
 — +3.1%
MRNA
Moderna
 Jun 07, 2025 HOLD Hold
+8.4% avg upside
38 analysts
 — +68.6%
TPST
Tempest Therapeutics
 Apr 25, 2025 HOLD Buy
+1669.9% avg upside
18 analysts
 — -76.9%
NCNA
Nucana
 Apr 25, 2025 HOLD Strong Buy
+559.7% avg upside
9 analysts
 — -98.1%
IMUX
Immunic
 Mar 29, 2025 BUY Strong Buy
+166.0% avg upside
21 analysts
$1.20
91.61% Downside
 +0.0%
RNTX
Rein Therapeutics
 Dec 29, 2022 HOLD Strong Buy
+1064.9% avg upside
5 analysts
 — +63.1%
PVLA
Palvella Therapeutics
 Jan 03, 2022 BUY Strong Buy
+45.3% avg upside
27 analysts
 — ·
ATRA
Atara Biotherapeutics
 Dec 07, 2021 BUY Buy
+79.6% avg upside
18 analysts
 — -74.0%
ATNM
Actinium Pharmaceuticals
 Nov 19, 2021 BUY Strong Buy
+633.6% avg upside
11 analysts
 — +56.6%
BIIB
Biogen
 Jul 23, 2021 BUY Buy
+25.1% avg upside
51 analysts
 — -36.6%
NKTR
Nektar Therapeutics
 Jun 11, 2021 BUY Buy
+16.5% avg upside
25 analysts
 — -81.2%
🔒 33 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Matt Phipps — Frequently Asked Questions
How accurate are Matt Phipps's stock ratings?
Based on the calls 13Foresight could measure, about 36% of Matt's ratings were profitable over a one-year hold, with an average return of -4.1% per rating, or -132.3% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Matt ranked on 13Foresight?
Matt Phipps is currently ranked #2458 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Matt cover?
Matt most recently has ratings on INCY, CNTX, GMAB, CLYM, EVMN, CGEM, AUTL, JBIO, JSPR, UPB, INSM, KROS and 26 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.